Company intelligence / Profile preview

DRGT

Dublin, Ireland

Ownership: Private
Employees: ~30
Development stage: Other

Overview

DRGT (Drug Rediscovery and Genetic Targeting) is a specialty pharmaceutical company that utilizes its proprietary Super-API technology to improve the clinical performance of established drug compounds. By enhancing the solubility and bioavailability of poorly soluble drugs, DRGT develops products with faster onset of action and improved safety profiles. The company's lead asset, DRGT-06, is a high-bioavailability formulation of meloxicam designed for the management of acute and chronic pain. DRGT was acquired by Viatris (formerly Mylan) in 2020 to strengthen its portfolio of complex therapeutics and pain management solutions.

Therapeutic areas: RheumatologyImmunologyNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

1 asset

DRGT-46

Unknown

Partnerships

Viatris

Beyond the preview

Go deeper on DRGT.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DRGT.

Explore the full profile